07:00 , May 4, 2009 |  BC Week In Review  |  Company News

Amorfix, BioMosaics Inc. deal

The companies will use Amorfix's Epitope Protection technology with BioMosaics' mAbs against glypican 3 (GPC3) to develop a blood-based assay for the early detection of hepatocellular carcinoma (HCC). BioMosaics will commercialize the resulting assay. Amorfix...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

BioMosaics Inc. sales and marketing update

BioMosaics Inc. , Burlington, Vt.   Business: Diagnostic   BioMosaics launched two products to detect the cancer marker glypican-3 in tissue and serum: a monoclonal antibody for immunohistochemistry testing and an ELISA assay.  ...
08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

BioMosaics Inc., Toronto Hospital deal

BioMosaics acquired from the hospital exclusive worldwide rights to a diagnostic for hepatocellular carcinoma (HCC) that uses a monoclonal antibody to glypican 3 (GPC3) . GPC3 is a glycophosphatidyl inositol-linked membrane-associated heparan sulfate-binding molecule that...